1. Introduction {#sec1}
===============

Bacitracin is a cyclic peptide antibiotic mainly produced by *Bacillus subtilis* and *Bacillus licheniformis,* and is synthesized by non-ribosomal polypeptide synthetase (NRPS) with 11 kinds of amino acids (Orn, D-Phe, His, D-Asp, Asn, Lys, D-Glu, Cys, Leu, Ile and Val) as precursors. Bacitracin synthetase was encoded by gene cluster *bacTABC*, in which, *bacA* is used to activate and polymerize five kinds of amino acids (Ile, Cys, Leu, D-Glu and Ile) at bacitracin tail, *bacB* and *bacC* are responsible for activating and polymerizing seven kinds of amino acids in heptapeptide loop. However, the relationship between function of *bacT* and bacitracin synthesis is unclear. In addition, bacitracin is also composed of multiple components (bacitracin A, B1, B2, etc.), of which bacitracin A has the highest property ([@bib18]). Acting as a broad spectrum antibiotic, bacitracin inhibits gram-positive and some gram-negative bacteria by repressing bacterial cell wall synthesis. Additionally, this antibiotic is safe to use, has good stability and low-absorption rates ([@bib14]; [@bib26]), and is therefore widely used in feed additives.

With the rapid development of synthetic biology and metabolic engineering, several strategies have been developed to enhance target metabolite production ([@bib16]; [@bib33]; [@bib38]). For bacitracin, deleting branch chain amino acid (BCAA) transporter gene, *yhdG* and overexpressing the BCAA permease, BrnQ have been shown to improve intracellular BCAA accumulations, leading to 11% and 10.43% increases in bacitracin yields, respectively ([@bib18]; [@bib40]). The Lys and Orn synthetic pathways were also strengthened, which led to 28.95% and 16.5% increases of bacitracin yields ([@bib34]; [@bib37]). In addition, metabolic engineering of transcriptional factors and strengthening tricarboxylic acid cycle elements also improved precursor amino acid supplies for bacitracin production ([@bib12]; [@bib21]). Based on these observations, insufficient BCAA supplies may be a bottleneck for efficient bacitracin production, however as yet, no studies have been performed to enhance bacitracin yield via the systematic engineering of BCAA supply modules.

Compared to the synthetic pathways of other amino acids, the synthetic pathways for BCAAs are efficient and economical, since other pathways require more enzymes to synthesize a single kind of amino acid, while only eight enzymes (IlvA, IlvBN, IlvC, IlvD, YbgE, LeuA, LeuB and LeuCD) are required for BCAA syntheses ([Fig. 2](#fig2){ref-type="fig"}), and BCAA aminotransferase serves as the common enzyme for Ile, Leu and Val syntheses ([@bib1]). Recently, several metabolic engineering approaches have been conducted to improve BCAA production. Vogt et al. constructed a feedback-resistant 2-isopropylmalate synthetase, LeuA^fbr^ for Leu production, with Leu yield further enhanced by deleting *ltbR* and *iolR*, reducing citrate synthetase activity and introducing a feedback-resistant IlvN^fbr^ ([@bib29]). By overexpressing the feedback-resistant threonine dehydratase IlvA^fbr^ and acetohydroxy acid synthetase IlvBN^fbr^, L-Ile titer produced by *Corynebacterium glutamicum* JH13-156 reached 30.7 ​g/L, an increase of 131.7% ([@bib36]), and similarly, improving NADPH generation was also effective for L-Ile production ([@bib27]). Additionally, Chen et al. showed that deletion of *aceE*, *alaT*, *ilvA,* and overexpression of *ilvB*, *ilvN*, *ilvC* and *lrp*, was beneficial for L-Val production in *C. glutamicum* (ATCC 13869), and authors also indicated that overexpression of BCAA transporter, BrnFE, promoted L-Val production ([@bib13]). Moreover, L-Val yield was increased to 0.47 ​mmol/L by blocking three branched pathways (*ilvA*, *leuA* and *ldh*) in *B. licheniformis* by our group ([@bib19]).

*B. licheniformis* DW2 is an industrial strain used for bacitracin production ([@bib30]). Several strategies have been developed to improve bacitracin yield in our laboratory ([@bib12]). In this study, we sought to improve bacitracin yield via systematically engineering BCAA supply modules, including strengthening BCAA synthetic pathways, identifying and modifying BCAA transporters and manipulating the Leu-responsive family regulator, *lrpC*. We demonstrated that strengthening BCAA supplies was efficient in enhancing bacitracin production, and we provided a promising strain for industrial production of bacitracin.

2. Materials and methods {#sec2}
========================

2.1. Strains, plasmids and cultivation conditions {#sec2.1}
-------------------------------------------------

The strains and plasmids used in this research were provided in [Table 1](#tbl1){ref-type="table"}. *B. licheniformis* DW2 (CCTCC M2011344) acts as the original strain for constructing recombinants. The vector T~2~(2)-Ori was applied for gene deletion, promoter replacement and integration expression in *B. licheniformis*, and pHY300PLK serves as a *E. coli*-*Bacillus* shuttle expression vector for gene expression. The primers used for strain construction were listed in [Table S1](#appsec1){ref-type="sec"} (seeing in Supplementary Materials).Table 1The strains and plasmids used in this research.Table 1Strains and plasmidsRelevant propertiesSource of referenceStrains*Escherichia coli* DH5α*sup*E44 Δ*lac*U169 (f 80 *lacZ*ΔM15) *hsd* R17 *recA*1 *gyr*A96 *thi*1 *rel*A1This study*Bacillus licheniformis* DW2Wide-type CCTCC M2011344CCTCCDW2/pHY-ilvADW2 harboring IlvA expression vector pHY-ilvAThis studyDW2/pHY-ilvBNDW2 harboring IlvBN expression vector pHY-ilvBNThis studyDW2/pHY-ilvCDDW2 harboring IlvCD expression vector pHY-ilvCDThis studyDW2/pHY-leuADW2 harboring LeuA expression vector pHY-leuAThis studyDW2/pHY-leuBDW2 harboring LeuB expression vector pHY-leuBThis studyDW2/pHY-leuCDW2 harboring LeuC expression vector pHY-leuCThis studyDW2/pHY-leuDDW2 harboring LeuD expression vector pHY-leuDThis studyDW2/pHY-300DW2 harboring pHY300PLK, as control strainThis studyDW2/pHY-ilvBN^fbr^DW2 harboring IlvBN^fbr^ expression vector pHY-ilvBN^fbr^This studyDW2/pHY-leuA^fbr^DW2 harboring LeuA^fbr^ expression vector pHY-leuA^fbr^This studyDW2-ilvBN^fbr^IlvBN^fbr^ integration overexpression strainThis studyDW2-leuA^fbr^LeuA^fbr^ integration overexpression strainThis studyDW-BCAA1IlvBN^fbr^ and LeuA^fbr^ integration overexpression strainThis studyDW-BCAA1/pHY300DW-BCAA1 harboring pHY300PLKThis studyDW-BCAA1/pHY-IlvEDW-BCAA1 harboring IlvE expression vector pHY-IlvEThis studyDW-BCAA1/pHY-YbgEDW-BCAA1 harboring YbgE expression vector pHY-YbgEThis studyDW-BCAA1/pHY-YwaADW-BCAA1 harboring YwaA expression vector pHY-YwaAThis studyDW-BCAA2Overexpression of YbgE via promoter replacement in DW-BCAA1This studyDW2△yvbWDeleting *yvbW* in DW2This studyDW2/pHY-YvbWDW2 harboring YvbW expression vector pHY-YvbWThis studyDW2△BraBDeleting *braB* in DW2This studyDW2/pHY-BraBDW2 harboring BraB expression vector pHY-BraBThis studyDW-BCAA3Overexpression of YvbW via promoter replacement in DW-BCAA2This studyDW-BCAA4Overexpression of BraB via promoter replacement in DW-BCAA2This studyDW-BCAA5Simultaneously overexpressing YvbW and BraB via promoter replacement in DW-BCAA2This studyDW-BCAA6Deleting regulator gene *lrpC* in DW-BCAA5This studyPlasmidspHY300PLK*E. coli* and *B. s* shuttle vector; Amp^r^, Tet^r^Lab collectionT~2~(2)-Ori*Bacillus* knockout vector; Kan^r^Lab collectionpHY-ilvAIlvA expression vcctor based on pHY300PLKThis studypHY-ilvBNIlvBN expression vcctor based on pHY300PLKThis studypHY-ilvCDIlvCD expression vcctor based on pHY300PLKThis studypHY-leuALeuA expression vcctor based on pHY300PLKThis studypHY-leuBLeuB expression vcctor based on pHY300PLKThis studypHY-leuCLeuC expression vcctor based on pHY300PLKThis studypHY-leuDLeuD expression vcctor based on pHY300PLKThis studypHY-ilvBN^fbr^IlvBN^fbr^ expression vcctor based on pHY300PLKThis studypHY-leuA^fbr^LeuA^fbr^ expression vcctor based on pHY300PLKThis studypHY-IlvEIlvE expression vcctor based on pHY300PLKThis studypHY-YbgEYbgE expression vcctor based on pHY300PLKThis studypHY-YwaAYwaA expression vcctor based on pHY300PLKThis studyT~2~-::ilvBN^fbr^T~2~(2)-Ori-*ilvBN*^fbr^(A ​+ ​*tnrA* ​+ ​B); to overexpress *ilvBN*^fbr^This studyT~2~-::leuA^fbr^T~2~(2)-Ori-*leuA*^fbr^(A ​+ ​*tnrA* ​+ ​B); to overexpress *leuA*^fbr^This studyT~2~-PbacA-PybgET~2~(2)-Ori-PybgE(A ​+ ​PbacA ​+ ​B); to replace the promoter of *ybgE* by PbacAThis studyT~2~-PbacA-PyvbWT~2~(2)-Ori-PyvbW(A ​+ ​PbacA ​+ ​B); to replace the promoter of *yvbW* by PbacAThis studyT~2~-PbacA-PbraBT~2~(2)-Ori-PbraB(A ​+ ​PbacA ​+ ​B); to replace the promoter of *braB* by PbacAThis studyT~2~-lrpCT~2~(2)-Ori-*lrpC*(A ​+ ​B); to delete *lrpC*This study

*B. licheniformis* and *E. coli* were cultivated at 37 ​°C, and Luriae-Bertani (LB) medium served as the basic medium for strain cultivation, when necessary, adding with corresponding antibiotic (20 ​mg/L kanamycin or 20 ​mg/L tetracycline). The medium for bacitracin production contains (g/L) 100 soybean meal, 45 corn starch, 1 (NH~4~)~2~SO~4~, and 6 CaCO~3~, with natural pH. The seed was cultivated in a 250 ​mL flask containing 20 ​mL LB medium to OD~600~ 4.0--4.5, and transferred (1 ​mL) into fermentation medium, and then cultivated at 230 ​rpm for 48 ​h.

As for identifying the transportation modules of BCAA permeases, YvbW and BraB, the medium E (ME medium, pH 7.2) containing (g/L) 20 glucose, 20 sodium glutamate, 10 sodium citrate, 7 NH~4~Cl, 0.5 K~2~HPO~4~·3H~2~O, 0.5 MgSO~4~·7H~2~O, 0.04 FeCl~3~·6H~2~O, 0.104 MnSO~4~·H~2~O, 0.15 CaCl~2~·2H~2~O was applied ([@bib7]).

2.2. Construction of gene overexpression strain {#sec2.2}
-----------------------------------------------

The construction procedure of gene overexpression strain was referred to our previously reported method ([@bib10]), and IlvB overexpression strain was served as an example. Briefly, P43 promoter from *B. subtilis* 168, gene *ilvB* and *amyL* terminator from *B. licheniformis* DW2, were amplified with corresponding primers, and fused by Splicing Overlap Extension (SOE)-PCR. The fused fragment was inserted into pHY300PLK at restriction sites *Eoc*RI/*Xba*I, diagnostic PCR and DNA sequence confirmed that IlvB expression vector pHY-ilvB was constructed successfully. Then, pHY-ilvB was electro-transferred into *B. licheniformis* DW2 to attain IlvB overexpression strain, named as DW2/pHY-ilvB. Similarly, other genes (*ilvA*, *ilvCD*, *leuA*, *leuB*, *leuC*, *leuD*, *ilvE*, *ybgE*, *ywaA*) overexpression strains were constructed according to the same method, and DW2/pHY300 was obtained to serve as the control.

2.3. Gene deletion in *B. licheniformis* {#sec2.3}
----------------------------------------

The procedure for constructing gene deletion strain of *B. licheniformis* was referred to our previously reported method ([@bib9]), and BCAA permease gene, *yvbW* deletion strain was served as an example. In brief, the upstream and downstream homogenous arms of *yvbW* were amplified, fused by SOE-PCR. After digested by *Sac*I/*Xba*I, the fragments were then inserted into T~2~(2)-Ori. Plasmid extraction and DNA sequence confirmed that *yvbW* deletion vector was constructed successfully, named as T~2~-yvbW.

Then, T~2~-yvbW was electro-transferred into *B. licheniformis* DW2, and the positive transformant was picked and cultivated in LB medium with 20 ​mg/L kanamycin at 45 ​°C, and sub-cultured for three generations. The single-cross transformant was verified, and then cultivated at 37 ​°C without antibiotic addition for several generations. The kanamycin-sensitive colonies were picked, diagnostic PCR and DNA sequence were applied to confirm that *yvbW* deficient strain was constructed successfully, named as DW2△yvbW. Similarly, another BCAA permease gene, *braB*, was successfully deleted in DW2 by the same method, named as DW2△braB.

2.4. Construction of promoter replacement strain {#sec2.4}
------------------------------------------------

The construction procedure of promoter PybgE replacement strain was accorded to the previous research ([@bib25]). Briefly, the up-stream and down-stream homogenous arms of promoter PybgE, bacitracin synthetase operon promoter PbacA ([@bib28]), were amplified by corresponding primers, after fused by SOE-PCR, the fused fragment was inserted into T~2~(2)-Ori to form the promoter replacement vector T~2~-PbacA-PybgE. Then, T~2~-PbacA-PybgE was electro-transferred into *B. licheniformis*, and promoter replacement strain was attained via homologous double crossover, the same as that of gene deletion.

2.5. Construction of gene integration overexpression strain {#sec2.5}
-----------------------------------------------------------

To construct the strain which overexpressing multiple genes together, individual genes mediated by P43 promoter were integrated into chromosome of *B. licheniformis*, following to previously reported protocol ([@bib34]), and verified by diagnostic PCR and DNA sequence.

2.6. Analytical methods {#sec2.6}
-----------------------

Bacitracin yield was measured by Agilent 1260 high performance liquid chromatography (HPLC) equipped with C18 column (ZORBAX SB-C18), and cell biomass was measured by dilution coating. The concentrations of extracellular and intracellular amino acids were determined by Agilent 7890B gas chromatography (GC), equipped with Trace TR-5 column (30 ​m ​× ​0.25 mm ​× ​0.25 ​μm) and flame ionizationdetector (FID) at 280 ​°C ([@bib34]). The concentrations of byproducts acetic acid, acetoin and 2,3-butanediol were determined by GC ([@bib39]). The activities of acetolactate synthetase and 2-isopropylmalate synthetase were measured via according to previous researches ([@bib29]; [@bib36]). Gene transcriptional levels of recombinant strains were measured by RT-qPCR, comparing with those of control strains after being normalized to reference gene *16S rDNA* ([@bib10]), and primers used for RT-qPCR were listed in [Table S2](#appsec1){ref-type="sec"} (seeing in Supplementary Materials).

2.7. Statistical analysis {#sec2.7}
-------------------------

All data were conducted to analyze the variance at P ​\< ​0.05 and P ​\< ​0.01, and a *t*-test was applied to compare the mean values using the software package, Statistica 6.0. Each experiment was repeated at least three times, and data are represented as the means of three replicates, and bars represented the standard deviations, ∗, P ​\< ​0.05; and ∗∗, P ​\< ​0.01 indicated the significance levels between experimental and control groups ([@bib9]).

3. Results and discussion {#sec3}
=========================

3.1. The effects of exogenous BCAA addition on bacitracin production {#sec3.1}
--------------------------------------------------------------------

Acting as precursor amino acids of bacitracin, BCAA supplies may serve as critical roles on bacitracin synthesis. Firstly, to evaluate the important role of BCAA supplies on bacitracin production, 40 ​mg/L of Ile, Leu and Val were individually added into bacitracin fermentation medium at 6, 12, 18, 24 ​h in separate experiments. Our data suggested that Ile and Leu additions benefited bacitracin synthesis, however, Val addition had no effect on its production ([Fig. 1](#fig1){ref-type="fig"}A). Then, different Ile and Leu concentrations were tested at 18 ​h, with 50 ​mg/L Ile and 40 ​mg/L Leu, bacitracin yields were increased by 13.40% and 8.75%, respectively, compared with the control group. These data indicated that Ile and Leu may act as the limiting precursors for bacitracin synthesis.Fig. 1**Effects of Ile, Leu and Val additions on bacitracin production. A:** Effects of 40 ​mg/L Ile, Leu and Val addition at different time points on bacitracin production, respectively. **B:** Effects of different concentrations of Ile and Leu additions at 18 ​h on bacitracin production, respectively. Each experiment was repeated at least three times, and data are represented as the means of three replicates and bars represent the standard deviations, ∗, P ​\< ​0.05; and ∗∗, P ​\< ​0.01 indicate the significance levels between recombinant strains and control strain.Fig. 1Fig. 2Metabolic engineering of BCAA synthetic, transportation and regulation modules for enhanced production of bacitracin in *B. licheniformis* DW2.Fig. 2

3.2. Strengthening BCAA synthetic pathways improved bacitracin yields {#sec3.2}
---------------------------------------------------------------------

### 3.2.1. The effects of overexpressing BCAA synthetic pathway genes on bacitracin production {#sec3.2.1}

A schematic diagram of BCAA synthetic pathways in *B. licheniformis* DW2 is shown in [Fig. 2](#fig2){ref-type="fig"}. The following genes, *ilvA*, *ilvBN*, *ilvCD*, *leuA*, *leuB*, *leuC* and *leuD* were overexpressed to evaluate the effects of BCAA synthetic pathway enhancement on bacitracin production. Based on our results ([Fig. 3](#fig3){ref-type="fig"}A), overexpression of these genes enhanced bacitracin yields to 10.85%, 17.22%, 7.76%, 16.15%, 9.36%, 7.70% and 8.91%, respectively, higher than that of DW2/pHY300 (662.43 U/mL). Of these recombinant strains, the IlvBN and LeuA overexpression strains DW2/pHY-ilvBN and DW2/pHY-leuA showed the best performances, and agreed with previous researches showing that IlvBN and LeuA were critical in Ile and Leu production, respectively ([@bib29]; [@bib36]). Similarly, strengthening IlvBN and LeuA expression also benefited cell growth ([Fig. S1](#appsec1){ref-type="sec"}), as cell biomasses of DW2/pHY-ilvBN and DW2/pHY-leuA showed 9.32% and 9.30% higher than that of DW2/pHY300, respectively.Fig. 3**Effects of strengthening BCAA synthetic pathways on bacitracin production. A:** Effects of overexpression of *ilvA*, *ilvBN*, *ilvCD*, *leuA*, *leuB*, *leuC*, *leuD* on bacitracin yields, **B:** overexpression of the feedback resistant IlvBN^fbr^ and LeuA^fbr^ improved bacitraicn production, **C:** The concentrations of intracellular BCAAs, **D:** The concentrations of extracellular BCAAs. Each experiment was repeated at least three times, and data are represented as the means of three replicates and bars represent the standard deviations, ∗, P ​\< ​0.05; and ∗∗, P ​\< ​0.01 indicate the significance levels between recombinant strains and control strain.Fig. 3

### 3.2.2. Construction of the feedback-resistant IlvBN^fbr^ and LeuA^fbr^ and their effects on bacitracin production {#sec3.2.2}

Generally, genes in amino acid synthetic pathways are feedback inhibited by the increasing target concentrations ([@bib1]). Previously, to eliminate feedback inhibition by Ile, Yin et al. constructed the feedback-resistant IlvA^fbr^ and IlvBN^fbr^, to further improve Ile production in *C. glutamicum* ([@bib36]). Also, similar tactics were applied to modify LeuA, to resist the inhibition effects of Leu ([@bib29]). In this study, three amino acid exchanges (P167S, Q413E and F557W) were introduced to *ilvBN* to construct *ilvBN*^fbr^, and the relative feedback resistant LeuA^fbr^ was generated by two amino acid changes i.e. T425H and G428D. The strains DW2/pHY-ilvBN^fbr^ and DW2/pHY-leuA^fbr^ were constructed, and the corresponding bacitracin yields were 796.26 U/mL and 785.33 U/mL, slightly higher than those produced by DW2/pHY-ilvBN and DW2/pHY-leuA strains ([Fig. 3](#fig3){ref-type="fig"}B), respectively. Additionally, acetolactate synthase activity in DW2/pHY-ilvBN^fbr^ and 2-isopropylmalate synthase activity in DW2/pHY-leuA^fbr^ were enhanced by 54.46% and 41.23%, compared with those of DW2/pHY-ilvBN and DW2/pHY-leuA, respectively ([Table 2](#tbl2){ref-type="table"}), which positively correlated with bacitracin yields ([Fig. 3](#fig3){ref-type="fig"}B).Table 2The activities of acetolactate synthetase and 2-isopropylmalate synthetase in IlvBN and LeuA overexpression strains.Table 2StrainsAcetolactate synthetase (U/mL)2-isopropylmalate synthetase (U/mL)DW2/pHY30014.329.53DW2/pHY-ilvBN31.42--DW2/pHY-leuA--16.42DW2/pHY-ilvBN^fbr^48.53--DW2/pHY-leuA^fbr^--23.19

Furthermore, to eliminate the repression effects of free plasmids on cell growth and bacitracin synthesis ([@bib41]), *ilvBN*^fbr^ and *leuA*^fbr^ driven by P43 promoter were integrated into *B. licheniformis* DW2 chromosome to generate the recombinant strains, DW2-ilvBN^fbr^ and DW2-leuA^fbr^. The bacitracin yields of which reached 831.54 U/mL and 822.43 U/mL, 10.24% and 9.44% higher than that of DW2 (754.32 U/mL), respectively. Furthermore, *B. licheniformis* DW-BCAA1 was generated by simultaneously overexpressing IlvBN^fb*r*^ and LeuA^fb*r*^, and bacitracin yield reached 865.15 U/mL, an increase of 14.69% when compared to DW2. Moreover, the intracellular concentrations of Ile, Leu and Val in DW2-BCAA1 reached 13.43 ​mg/L, 9.74 ​mg/L and 11.98 ​mg/L, increased by 88.10%, 53.39% and 25.58%, respectively. Equally, the extracellular concentrations of Ile, Leu and Val were respectively increased by 29.06%, 16.41% and 13.56%, because of the enhancements of BCAA synthetic pathways.

### 3.2.3. Strengthening BCAA aminotransferase improved bacitracin production {#sec3.2.3}

As the last enzyme in the BCAA synthetic pathways ([@bib1]; [@bib6]), BCAA aminotransferase has critical roles in BCAA syntheses ([@bib15]). In this work, three BCAA aminotransferases, IlvE from *E. coli*, and YbgE and YwaA from *B. licheniformis*, were overexpressed in DW-BCAA1 strain, generating BCAA aminotransferase overexpression strains, DW-BCAA1/pHY-IlvE, DW-BCAA1/pHY-YbgE and DW-BCAA1/pHY-YwaA, respectively. Our experimental results showed that BCAA aminotransferase overexpression improved bacitracin yields, i.e. 8.62%, 14.66% and 11.02%, compared to DW-BCAA1/pHY300 (759.76 U/mL) ([Fig. 4](#fig4){ref-type="fig"}A), respectively.Fig. 4**Effects of BCAA aminotransferase overexpressions on bacitracin production. A:** Effects of *ilvE*, *ywaA* and *ybgE* overexperessions on bacitracin yields, **B:** Effects of replacing the promoter of *ybgE* by PbacA on bacitracin production, **C:** The concentrations of intracellular BCAAs, **D:** The concentrations of extracellular BCAAs. Each experiment was repeated at least three times, and data are represented as the means of three replicates and bars represent the standard deviations, ∗, P ​\< ​0.05; and ∗∗, P ​\< ​0.01 indicate the significance levels between recombinant strains and control strain.Fig. 4

Furthermore, the *ybgE* promoter in *B. licheniformis* BCAA1 was replaced by PbacA, a strong promoter previously confirmed in our group ([@bib28]), to generate DW-BCAA2. Fermentation results showed that bacitracin yield produced by DW-BCAA2 reached 892.54 U/mL, an increase of 18.32% and 3.17%, compared with DW2 and DW-BCAA1, respectively. In addition, intracellular and extracellular BCAA concentrations were all significantly enhanced ([Fig. 4](#fig4){ref-type="fig"}B and C). Previously, the BCAA aminotransferase activity of YbgE was much greater than YwaA, and it displayed higher affinity for Ile and Leu in *B. subtilis*, consistently, our results agreed with previous reports ([@bib6]; [@bib8]).

3.3. Engineering BCAA permeases, YvbW and BraB improved bacitracin production {#sec3.3}
-----------------------------------------------------------------------------

Amino acid transporters play important roles in the distribution and production of relative amino acids ([@bib32]; [@bib35]). Previously, Lys transporter LysE was shown to be a Lys exporter in *C. glutamicum*, with LysE overexpression significantly enhancing Lys yields ([@bib23]). Overexpression of BCAA transporter, BrnFE was effective for Val production in *C. glutamicum* ([@bib13]). The fermentation medium for bacitracin production contains 100 ​g/L soybean meal, which generates considerable amounts of free amino acids in fermentation broth ([@bib11]), therefore, engineering amino acid transporters may be an effective approach for bacitracin production. In our previous research, we observed that engineering Lys transporters, LysE, LysP and YvsH was beneficial for bacitracin synthesis, via improving intracellular Lys accumulation ([@bib34]). As for BCAAs, deletion of BCAA exporter gene, *yhdG*, improved intracellular BCAA accumulations and bacitracin yield ([@bib18]), and overexpression of another BCAA importer, BrnQ, also benefited bacitracin synthesis ([@bib40]). Here, *yvbW* and *braB* were annotated as BCAA permease genes in *B. licheniformis* DW2, however, the transport modes are not yet resolved, nor are their effects on bacitracin production. Here, we sought to clarify the transportation modes of YvbW and BraB, and then manipulating their actions to improve intracellular BCAA accumulation for bacitracin production.

### 3.3.1. Identification of transportation modes of the BCAA permeases, YvbW and BraB in *B. licheniformis* DW2 {#sec3.3.1}

The genes, *yvbW* and *braB* were knocked out in DW2, generating the mutant strains DW2△yvbW and DW2△braB. Gene overexpression strains DW2/pHY-yvbW and DW2/pHY-braB were also constructed. Our experimental results showed that bacitracin yields were decreased by 7.95% and 6.48% in *yvbW* and *braB* deletion strains, respectively, while YvbW and BraB overexpressions promoted bacitracin syntheses ([Fig. 5](#fig5){ref-type="fig"}A). Meantime, intracellular BCAA concentrations were increased and extracellular BCAA concentrations were decreased in *yvbW* and *braB* overexpression strains, respectively ([Fig. 5](#fig5){ref-type="fig"}B and [C](#fig5){ref-type="fig"}). Therefore, our results indicated YvbW and BraB may function as BCAA importers in *B. licheniformis* DW2.Fig. 5**Identification of BCAA permeases, YvbW and BraB, in *B. licheniformis* DW2. A:** Effects of overexpression and deletion of *yvbW* and *braB* on bacitracin production, **B:** The concentrations of intracellular BCAAs, **C:** The concentrations of extracellular BCAAs, **D:** The concentrations of extracellular BCAAs of DW2/pHY300, **E:** The concentrations of extracellular BCAAs of DW2/pHY-YvbW, **F:** The concentrations of extracellular BCAAs of DW2/pHY-BraB. Each experiment was repeated at least three times, and data are represented as the means of three replicates and bars represent the standard deviations, ∗, P ​\< ​0.05; and ∗∗, P ​\< ​0.01 indicate the significance levels between recombinant strains and control strain.Fig. 5

To test this hypothesis, all strains were cultivated in ME medium for 24 ​h, after which cells were washed and transferred into ME medium containing 1 ​mM Ile, Leu or Val. After this period, extracellular BCAA concentrations were measured for another 24 ​h. Our data revealed that concentrations of extracellular BCAAs dropped significantly in YvbW and BraB overexpression strains, when compared to DW2/pHY300 ([Fig. 5](#fig5){ref-type="fig"}D--F). The import rates of extracellular BCAAs were reduced in gene deletion strains ([Fig. S2](#appsec1){ref-type="sec"}). Moreover, YvbW appeared more suitable for Leu import, and BraB may have higher affinity for Ile import, however, both showed limited capabilities for Val import. Taken together, these results confirmed that YvbW and BraB acted as BCAA importers in DW2, suggesting they were efficient permeases for Leu and Ile import, respectively. In *B. subtilis*, the BCAA transporters, BcaP (YhdG in *B. licheniformis* DW2), BraB and BrnQ were implicated in BCAA uptake, with BcaP appearing to be the most efficient permease for Ile and Val import ([@bib3]). Additionally, these transporters, as well as the BCAA synthetase gene cluster, *ilv*-*leu*, were regulated by CodY in *B. subtilis* ([@bib3]). Moreover, YvbW is assumed to be a BCAA permease with high affinity for Leu transportation in *B. subtilis* ([@bib31]), however, no studies have yet to test and verify this mechanism. Our results confirmed that YvbW served as a BCAA importer in *B. licheniformis* DW2, and acted as the most efficient permease for Leu uptake.

### 3.3.2. Engineering the BCAA permeases, YvbW and BraB to improve bacitracin production {#sec3.3.2}

To further improve intracellular BCAA accumulations for bacitracin production, YvbW and BraB were overexpressed in DW-BCAA2, by replacing their promoters with PbacA, resulting in strains DW-BCAA3 and DW-BCAA4, respectively. After experimental analyses, our results ([Fig. 6](#fig6){ref-type="fig"}A) suggested that bacitracin yields produced by DW-BCAA3 and DW-BCAA4 were 941.42 U/mL and 949.12 U/mL, increased by 24.80% and 25.83% when compared with DW2, respectively. Additionally, a further strain DW2-BCAA5 was generated by a combinatorial overexpression strategy (overexpression of YvbW and BraB simultaneously), and bacitracin yield of which reached 988.52 U/mL, increased by 31.05% and 10.75% compared with those of DW2 and DW-BCAA2, respectively ([Fig. 6](#fig6){ref-type="fig"}A). Additionally, intracellular concentrations of Ile, Leu and Val were 21.43 ​mg/L, 16.64 ​mg/L and 15.43 ​mg/L, respectively, increased by 2.00-, 1.62- and 0.62-fold compared to DW-BCAA2 cells, while concentrations of extracellular BCAAs were all decreased ([Fig. 6](#fig6){ref-type="fig"}B and C).Fig. 6**Engineering BCAA permeases, YvbW and BraB, for enhancement production of bacitracin. A:** Strengthening YvbW and BraB expressions improved bacitracin production. **B:** The concentrations of intracellular BCAAs, **C:** The concentrations of extracellular BCAAs. Each experiment was repeated at least three times, and data are represented as the means of three replicates and bars represent the standard deviations, ∗, P ​\< ​0.05; and ∗∗, P ​\< ​0.01 indicate the significance levels between recombinant strains and control strain.Fig. 6

Previously, several amino acid transporters were engineered for target metabolite production, i.e. engineering LysE for Lys production and BrnFE for Val production ([@bib13]; [@bib23]). Here, high levels of free amino acids degraded from soybean meal remained in the fermentation broth ([@bib11]), and how to effectively utilize these free amino acids is a key factor for high-level production of bacitracin. Because of this, engineering amino acid transporters has proven to be effective for bacitracin synthesis ([@bib34]), and bacitracin yields were significantly enhanced by overexpressing the BCAA permeases, BraB and YvbW in this study, and we suggested that this strategy could be applied to the production of other metabolites.

3.4. Deletion of the leucine-responsive regulator gene, *lrpC* improved bacitracin production {#sec3.4}
---------------------------------------------------------------------------------------------

The leucine-responsive regulator LrpC, which is present in bacteria and archaea, is a negative regulator in several physiological processes ([@bib4]; [@bib22]). Similarly, genes in the BCAA synthetic (*ilvGMEDA*, *ilvIH* and *leuABCD*) and transportation pathways (*ilvJ* and *ygaZH*) are regulated by regulator LrpC in *E. coli* ([@bib24]). Chip-on-chip analysis confirmed that LrpC directly regulated BCAA transporter BrnFE in *C. glutamicum* ([@bib17]). In addition, deleting the *lrp* family regulator, *SACE*\_*lrp* strengthened BCAA accumulations, which further improved erythromycin production in *Saccharopolyspora erythrae*a ([@bib20]). In this study, *lrpC* was deleted in DW-BCAA5, resulting in DW-BCAA6. From our experimental results, bacitracin yield produced by DW-BCAA6 reached 1027.78 U/mL, an increase of 36.25%, when compared to DW2 ([Fig. 7](#fig7){ref-type="fig"}A). Equally, the transcriptional levels of BCAA permease, *brnQ*, were enhanced 1.65-fold ([Fig. 7](#fig7){ref-type="fig"}B). Furthermore, we also constructed a green fluorescent protein (GFP) expression vector, which driven by promoter PbrnQ ([Fig. 7](#fig7){ref-type="fig"}C), and then transferred into DW-BCAA5 and DW-BCAA6 respectively. Based on our results of [Fig. 7](#fig7){ref-type="fig"}D, green fluorescence intensities were significantly enhanced in DW-BCAA6, indicating the increased PbrnQ transcription in *lrpC* deletion strain. Collectively, these results suggested that PbrnQ was negatively regulated by regulator LrpC. Since BrnQ has been shown to be a BCAA importer in *B. licheniformis* ([@bib40]), the increased BrnQ expression benefited intracellular BCAA accumulations, which promoted bacitracin synthesis in *lrpC* deletion strain. Meantime, *lrpC* deletion had no effect on *ilvA*, *ilvB* and *ilvCD* transcription in BCAA synthetic pathways ([Fig. S3](#appsec1){ref-type="sec"}).Fig. 7**Effects of *lrpC* deletion on bacitracin synthesis. A:** Deletion of *lrpC* improved bacitracin yield, **B:** The transcriptional level of BCAA transporter gene *brnQ*, **C**: The schematic diagram of GFP expression vector mediated by promoter PbrnQ, **D**: The green fluorescence intensities of recombinant strains. Each experiment was repeated at least three times, and data are represented as the means of three replicates and bars represent the standard deviations, ∗, P ​\< ​0.05; and ∗∗, P ​\< ​0.01 indicate the significance levels between recombinant strains and control strain.Fig. 7

Additionally, BCAA addition experiments were conducted in DW-BCAA6, our results in [Fig. S4](#appsec1){ref-type="sec"} suggested that addition of Ile, Leu or Val could not further improve bacitracin yield of DW-BCAA6, suggested that intracellular BCAAs were adequate for bacitracin synthesis via our metabolic engineering approaches.

3.5. Fermentation parameters for *B. licheniformis* DW2 and DW-BCAA6 {#sec3.5}
--------------------------------------------------------------------

We assessed several outputs of *B. licheniformis* DW2 and DW-BCAA6 in terms of bacitracin production. As shown in [Fig. 8](#fig8){ref-type="fig"}A, bacitracin yields produced by DW-BCAA6 were higher than DW2 throughout the fermentation process, with the maximum bacitracin yield for DW-BCAA6 was increased to 1029.83 U/mL, a 36.52% increase compared to DW2. Strengthening BCAA supplies was also beneficial for fatty acid synthesis and cell growth ([@bib5]), and the maximum cell biomass for DW-BCAA6 was 452.42 ​× ​10^8^ ​CFU/mL, 12.73% higher than that of DW2 (401.33 ​× ​10^8^ ​CFU/mL). In addition to the critical role of BCAAs on metabolite synthesis and cell growth, the strategies outlined in this research could be extended to the efficient production of heterologous proteins and other metabolites in future work. The bacitracin yield per DW-BCAA6 cell was 2.28 ​× ​10^−8^ U/CFU, an increase of 21.11% compared to DW2. Furthermore, the concentrations of intracellular Ile, Leu and Val were 23.31 ​mg/L, 18.43 ​mg/L and 16.41 ​mg/L in DW-BCAA6, increased by 2.26-, 1.90- and 0.72-fold compared with DW2 (7.14 ​mg/L, 6.35 ​mg/L and 9.54 ​mg/L) ([Fig. 8](#fig8){ref-type="fig"}B and C), respectively. Of three amino acids (Ile, Leu and Val), Ile had the largest increase ratio (2.26-fold) in DW-BCAA6, compared to Leu (1.90-fold) and Val (0.72-fold). Since Ile acts as a critical constituent amino acid of bacitracin A, the most active component in bacitracin family ([@bib18]), in this study, bacitracin A proportion of DW-BCAA6 was 56.37%, increased by 24.62% compared with DW2 (45.27%), indicated that strengthening Ile supply not only improve bacitracin yield, but also bacitracin A potency is enhanced in DW-BCAA6, and which is beneficial for the increase of bacitracin effectiveness. Additionally, the intracellular concentrations of other precursor amino acids (Asn, Cys and Lys) were also significantly enhanced in DW-BCAA6 cells, compared with those of DW2 ([Fig. S5](#appsec1){ref-type="sec"}). In addition, since acetic acid, acetoin and 2,3-butanediol were the main byproducts during *Bacillus* fermentation ([@bib39]), our results implied that the yields of acetic acid, acetoin and 2,3-butanediol by-products were significantly decreased, when compared with DW2 ([Fig. 8](#fig8){ref-type="fig"}D).Fig. 8**Fermentation processes of *B. licheniformis* DW2 and DW-BCAA6. A:** Bacitracin yields and cell biomasses of DW2 and DW-BCAA6 during bacitracin production, **B:** The concentrations of intracellular BCAAs, **C:** The concentrations of extracellular BCAAs, **D:** The concentrations of main byproducts, acetic acid, acetoin and 2,3-butanediol. Each experiment was repeated at least three times, and data are represented as the means of three replicates and bars represent the standard deviations, ∗, P ​\< ​0.05; and ∗∗, P ​\< ​0.01 indicate the significance levels between recombinant strains and control strain.Fig. 8

4. Conclusions {#sec4}
==============

Precursor amino acid supplies serve critical roles in bacitracin production. In this research, Ile and Leu were confirmed as limiting amino acids for bacitracin synthesis, suggesting that strengthening BCAA synthetic pathways could improve bacitracin yield. Furthermore, the BCAA transporters, YvbW and BraB were identified as BCAA importers, and overexpression of these importers enhanced intracellular BCAA accumulations and bacitracin yields. Additionally, deletion of the leucine-responsive regulator, *lrpC* improved BrnQ expression, and further improved intracellular BCAA supplies and bacitracin production. Finally, bacitracin yields produced by DW-BCAA6 reached 1029.83 U/mL, an increase of 36.52% when compared with DW2. This is the highest bacitracin yield currently reported in the literature. This study has outlined an efficient strain improvement strategy to improve bacitracin yield, and a promising *B. licheniformis* DW-BCAA6 strain was generated for the industrial production of bacitracin.
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